Osimertinib is a covalent, orally active, irreversible EGFR inhibitor that selectively targets mutant EGFR with IC50s of 12 nM for L858R and 1 nM for L858R/T790M. It effectively overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Osimertinib mesylate is used for the treatment of EGFR-mutated non-small-cell lung cancer, demonstrating potent antitumor activity. Reagent grade, for research use only.
Usually ships within 24 hours.